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T H E  LA N C ET
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familial adenomatous polyposis
H F A Vasen, R B van der Luijt, J  F M Slors, E Buskens, P de Ruiter, C G M Baeten, W R Schouten, H J  M Oostvogel, 
J H C Kuijpers, C M J  Tops, P Meera Khan
Summary
i
Background In familial adenomatous polyposis the only 
curative treatment is colectomy, and the choice of 
operation lies between restorative proctocolectomy (RPC) 
and colectomy with ileorectal anastomosis (IRA). The RPC 
procedure carries a higher morbidity but, unlike IRA, 
removes the risk of subsequent rectal cancer. Since the 
course of familial adenomatous polyposis is influenced by 
the site of mutation in the polyposis gene, DNA analysis 
might be helpful in treatment decisions.
Methods We evaluated the Incidence of rectal cancer in 
polyposis patients who had undergone IRA, and examined 
whether the requirement for subsequent rectal excision 
because of cancer or uncontrollable polyps was related to 
the site of mutation.
Findings Between 1956 and mid-1995, 225 patients 
registered at the Netherlands Polyposis Registry had 
undergone IRA. In 87 of them, a pathogenetic, mutation 
was detected. 72 patients had a mutation located before 
codon 1250 and 15 patients after this codon, The 
cumuiative risk of rectal cancer 20 years after surgery was 
12%, and at that time 42% had undergone rectal excision. 
The risk of secondary surgery was higher in patients with 
mutations In the region after codon 1250 than in patients 
with mutations before this codon (relative risk 2-7, 
p<0*05).
Interpretation On this evidence, IRA should be the primary 
treatment for polyposis in patients with mutations before 
codon 1250, and RPC in those with mutations after this 
codon.
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Introduction
Familial adenomatous polyposis (FAP) or Bussey- 
Gardner polyposis1 is an autosomal dominant disease 
characterised by hundreds of adenomas in the colon and 
by various extracolonic features.2 The disease is due to a 
mutation in the adenomatous polyposis coli (APC) gene 
which is located on chromosome 5 .v‘ The APC gene 
consists of 15 coding exons and probably influences 
interactions between cells. Most patients develop 
adenomatous polyps in their colon in the second and 
third decade of life2 and if untreated they get colorectal 
cancer in their thirties. We now know that individuals 
with identical mutations can show differences in 
phenotypic expression of the disease;'''1" nevertheless, 
several investigators report correlations between 
mutations occurring within specific regions of APC and 
the phenotypic expression. Mutations within exons 3 and 
4 are associated with a less severe form of FAP 
characterised by a low number of colorectal adenomas 
and a late age of onset of colorectal cancer.7 Nagase8 
reports that patients with mutations located in a region 
between codons 1250 and 1464 at exon 15 tend to have 
more than 5000 adenomatous polyps and to develop 
colorectal cancer at an average age of 34. Whereas those 
with mutations outside this region have fewer than 2000 
polyps and develop colorectal cancer at 41*8 years. A 
severe form of FAP has been associated with a deletion in 
codon 13091' and with mutations after codon 1250.IO,U
Might information on the location of the mutation be 
useful in determining the most appropriate surgical 
treatment? There has been a long debate about the extent 
of colonic surgery. If the rectum is carpeted with polyps 
or if the patient is unlikely to attend regularly for follow- 
up, there is a good case for restorative proctocolectomy 
(RPC). If the rectum is relatively free of adenomas, 
colectomy with ileorectal anastomosis (IRA) is the most 
attractive surgical procedure because of its satisfactory 
functional results. A drawback of IRA, however, is the 
substantial risk of cancer in the residual rectum;1 
moreover, a high proportion of the patients need rectal 
excision because of uncontrollable polyps. In the present 
study, we evaluated the cumulative risk of rectal cancer in 
a large series of patients ín the Netherlands. We also 
assessed the rate of rectal excision after IRA and whether 
the probability of secondary surgery is associated with the 
location of the mutation.
Methods
In 1985 a registry of families with familial adenomatous polyposis 
was set up in die Netherlands, 11 and by July 1, 1995, genealogical 
studies had been performed in 200 families with FAP referred 
from all parts of the country, Medical and pathological data were 
collected to verify the family history. Data collection was 
complete in 150 of the 200 families and these families were 
selected for the present study.
Between 1956 and m id-1995, 230 patients had IRA 
performed as a primary procedure for polyposis and 81
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underwent RPC. In all cases the diagnosis of FAP was confirmed 
by the presence of more than 100 adenomatous polyps and/or the 
identification of a mutated APC gene. The surgical operations 
were done in hospitals all over the Netherlands. Before 1990, in 
most centres, the preferred treatment of polyposis patients with 
few rectal polyps was IRA.
For risk assessment, patients who had an IRA were studied 
with respect to their risk of developing rectal cancer or requiring 
excision of the rectum. The data were analysed by survival 
analysis methods. Observation time was up to the date of last 
contacts death, the date of diagnosis of rectal cancer, the date of 
rectal excision, or the closing date of the study. Differences in 
risk of undergoing rectal excision were tested for statistical 
significance by the log rank test. Mutation studies of the APC 
gene conducted in the families registered at the Dutch Polyposis 
Registry have been described elsewhere.
Results
Of the 230 patients who had an IRA, 5 had follow-up of 
less than one year after surgery and were excluded. The 
remaining 225 had a mean follow-up of 11 yr (range 
1-38). Mean age at surgery was 28*3 yr (range 11-70). 16 
of these patients developed a rectal cancer (mean age 45 
yr; range 29-61). Of these 16 patients, information on 
screening was available in 12: 11 had undergone 
surveillance within the previous 12 months. The interval 
since the last endoscopic examination ranged from 3 to 14 
months (mean 8-8 months). Figure 1 shows the 
cumulative risk of developing rectal cancer by years of 
follow-up after surgery. At 10, 15, 20, and 25 years after 
surgery the cumulative risks were 3*9% (95% confidence 
interval 0*9-6*8%), 10*4% (4-5-16-3%), 12*1% 
(5-4-18-8%), and 25-8% (6*6-45-1%). Seven of the 16 
rectal cancer patients died, six from the cancer and one 
from postoperative complications. In 45 of the 225 
patients the rectum had to be removed because of 
recurrent polyps (n=29, mean age: 33 yr) or rectal cancer 
(n=16). The cumulative risk of rectal excision 103 15, and 
20 years after IRA was 15*0% (95% Cl 9*6-20*3%), 
32-2% (23*9-40*6%), and 42-2% (30-0-54-4%).
Mutation analysis
DNA analysis was conducted in 105 of the 150 polyposis 
families and the pathogenic mutation was detected in 56 
families. 32 of these families had at least one member who 
underwent an IRA. 21 families including 72 patients with 
an IRA (group A) had a mutation before codon 1250 and 
the remaining 11 families including 15 individuals with an 
IRA (group B) had a mutation after this codon. 14 of the 
patients from group A and eight of the patients from 
group B required rectal excision because of rectal cancer 
of uncontrollable polyps. The cumulative risk of rectal 
excision by years of follow-up after surgery was 
significantly higher in group B than in group A (relative 
risk 2*7; log rank test p<0*05) (figure 2).
Discussion
Although non-steroidal anti-inflammatory drugs may 
have some beneficial effect on colonic adenomas, 17 
prophylactic surgery of the colon is still the only curative 
treatment for polyposis. Restorative proctocolectomy 
might seem the ideal operation. By removal of all or 
nearly all the large-bowel mucosa the risk of cancer can 
be almost completely avoided. There are disadvantages, 
however, and the most important are die greater 
morbidity and duration of convalescence than with IRA 
and the possible failure of the pouch—a complication that
Follow-up (yr)
Figure 1: Cumulative risk of rectal cancer after ileorectal
anastomosis over 25 years of follow-up
Bars are 95% confidence intervals.
requires an ileostomy. Because most of the FAP patients 
who need surgery are between 15 and 25 years of age, 
such a procedure would seriously interfere with their 
education and the development of social relationships. 
Selection of patients for IRA or RPC must therefore 
depend on the balance of pros and cons— the morbidity 
and the possible failure of RPC versus the risk of cancer 
in the remaining rectum after IRA. Several reports from 
the 1980s indicated that the risk of rectal cancer gradually 
increases with time and amounts to 10-55%) after 20 
years of follow-up.12,13 One recent large-scale study from 
the Scandinavian countries covering 294 patients 
indicated a rectal cancer risk of 9% and 13% after 20 and 
25 years of follow-up, respectively.1” These data are in 
agreement with the results of the St Mark’s Polyposis 
Registry.13 The present study, which covered a 
comparable number of patients, yielded about the same 
risk at 20 years of follow-up, A Japanese study comprising 
320 patients showed a much higher risk, 37% after 20 
years.1*' An update of the St Mark’s series reveals that the 
risk of rectal cancer increases sharply after the age of 50 
years and is as high as 29% at age 60.20
Possible explanations for the discrepancies in incidence 
of rectal carcinoma between centres may include 
differences in the length of the rectal stump, the age at 
colectomy, and the quality of follow-up after surgery. In 
addition, variation in the definition of “uncontrollable” 
polyps between centres may contribute to the differences 
in rectal carcinoma incidence. The confidence intervals 
for the risks reported for a follow-up of 20 years or longer
Follow-up (yr)
Figure 2: Cumulative risk of rectal excision by years of 
follow-up after surgery in patients with mutations before codon
1250 (group A) and downstream from codon 1250 (group B)
*Log rank test.
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are very wide in most series (because of the small number 
of patients with such a long follow-up) and, in fact, the 
differences between the studies may fall within these 
limits. Could the rectal cancers have been prevented by 
regular rectoscopy? Almost all the patients with rectal 
cancer in the present series were under close surveillance 
and the interval since die last examination had been less 
than one year. The St Mark’s experience also indicated 
that the patients who developed rectal cancer were good 
compliers and most had undergone surveillance within 
the past six months.
The risk of rectal cancer is not the only factor in the 
choice of operation. An important consideration is the 
likelihood that, after IRA, a patient will later require rectal 
excision. In our series, 20 years after IRA almost half the 
patients had needed rectal excision for rectal cancer or for 
polyps that could not be controlled by polypectomy. If we 
were able to identify the patients who would need 
secondary surgery after IRA, such patients could be 
selected for a more definitive primary surgical procedure 
(RPC). Several studies have shown that the course of the 
disease in families with polyposis due to a mutation in the 
region after codon 1250 on exon 15, especially at codon 
1309, tends to be more aggressive than in families with 
mutations before this codon .811 Patients from such 
families may be at greater risk of recurrent polyps and 
rectal cancer after IRA. To test this hypothesis we 
evaluated the cumulative risk of rectal excision in a 
subgroup of patients with a known mutation. We found 
that the risk of rectal excision in patients with a mutation 
after 1250 is indeed higher than that in patients with a 
mutation before this codon.
We conclude that the results of DNA testing in relation 
to the phenotypic expression in the patient and family 
could be helpful in surgical decision-making. In patients 
with a mutation in the region after codon 1250, who are 
at high risk of rectal excision after IRA, RPC is the 
treatment of choice; whereas in patients with a mutation 
before codon 1250 colectomy and IRA is the preferred 
treatment,
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